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Interaction between Notch receptors and their 
ligands represents an evolutionarily conserved 
signaling pathway important not only for cell 
fate commitment in the developing thymus 
(Radtke et al., 2010) but also for regulating 
lineage decisions in hematopoiesis (Maillard 
et al., 2005). Genetic inactivation experiments 
showed that signaling mediated through the 
Notch 1 (N1) receptor plays an important role 
in T cell lineage commitment and maturation 
(Radtke et al., 1999, 2010; Wilson et al., 2001). 
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ble positive; DT, diphtheria 
toxin; imDC, immature DC; 
mDC, mature DC; MDP, mac-
rophage DC progenitor; NOD, 
nonobese diabetic; nTreg cell, 
natural Treg cell; pDC, plasma-
cytoid DC; PLN, pancreas-
draining LN; polyI:C, 
polyinosinic:polycytidylic acid; 
pStat5, phosphorylated Stat5; 
SP, single positive; T1D, type 1 
diabetes; tDC, thymic DC; 
TEC, thymic epithelial cell.
Dr. Steinman died on 30 September 2011. C. Lobry and  
G. Darrasse-Jèze contributed equally to this paper.
J. Waite and X. Liu contributed equally to this paper.
G. Darrasse-Jèze’s present address is Institut National de la 
Santé et de la Recherche Médicale Unité 768 and Faculté de 
Médecine, Université Paris Descartes, Sorbonne Paris Cité, 
75015 Paris, France.
Dll4–Notch signaling in Flt3-independent 
dendritic cell development  
and autoimmunity in mice
Fabienne Billiard,1 Camille Lobry,2 Guillaume Darrasse-Jèze,4  
Janelle Waite,1 Xia Liu,1 Hugo Mouquet,4 Amanda DaNave,1  
Michelle Tait,1 Juliana Idoyaga,5 Marylène Leboeuf,6  
Christos A. Kyratsous,1 Jacquelynn Burton,1 Julie Kalter,1  
Apostolos Klinakis,7 Wen Zhang,1 Gavin Thurston,1 Miriam Merad,6  
Ralph M. Steinman,5 Andrew J. Murphy,1 George D. Yancopoulos,1  
Iannis Aifantis,2,3 and Dimitris Skokos1
1Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591
2Department of Pathology and 3Howard Hughes Medical Institute, New York University, New York, NY 10016
4Laboratory of Molecular Immunology and 5Laboratory of Cellular Physiology and Immunology, The Rockefeller University, 
New York, NY 10065
6Immunology Institute, Department of Medicine, Department of Genes and Cell Medicine, Mount Sinai School of Medicine, 
New York, NY 10029
7Biomedical Research Foundation, Academy of Athens, Athens 115 27, Greece
Delta-like ligand 4 (Dll4)–Notch signaling is essential for T cell development and alternative 
thymic lineage decisions. How Dll4–Notch signaling affects pro-T cell fate and thymic dendritic 
cell (tDC) development is unknown. We found that Dll4 pharmacological blockade induces 
accumulation of tDCs and CD4+CD25+FoxP3+ regulatory T cells (Treg cells) in the thymic cortex. 
Both genetic inactivation models and anti-Dll4 antibody (Ab) treatment promote de novo 
natural Treg cell expansion by a DC-dependent mechanism that requires major histocompatibility 
complex II expression on DCs. Anti-Dll4 treatment converts CD4CD8c-kit+CD44+CD25 
(DN1) T cell progenitors to immature DCs that induce ex vivo differentiation of naive CD4+  
T cells into Treg cells. Induction of these tolerogenic DN1-derived tDCs and the ensuing expan-
sion of Treg cells are Fms-like tyrosine kinase 3 (Flt3) independent, occur in the context of 
transcriptional up-regulation of PU.1, Irf-4, Irf-8, and CSF-1, genes critical for DC differentia-
tion, and are abrogated in thymectomized mice. Anti-Dll4 treatment fully prevents type 1 
diabetes (T1D) via a Treg cell–mediated mechanism and inhibits CD8+ T cell pancreatic islet 
infiltration. Furthermore, a single injection of anti-Dll4 Ab reverses established T1D. Disease 
remission and recurrence are correlated with increased Treg cell numbers in the pancreas-
draining lymph nodes. These results identify Dll4–Notch as a novel Flt3-alternative pathway 
important for regulating tDC-mediated Treg cell homeostasis and autoimmunity.
© 2012 Billiard et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
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To explore the intriguing possibility that Dll4–Notch sig-
naling functions as an Flt3-alternative pathway in regulating 
DC development and Treg cell homeostasis, we used an anti-
Dll4 antibody (Ab; Billiard et al., 2011), as well as genetic 
inactivation models to suppress this pathway. We found that 
Dll4–Notch signaling blockade induced expansion of imma-
ture tDCs originating from DN1 pro-T cells, independently 
of Flt3 and in the context of transcriptional up-regulation of 
PU.1, Irf-4, Irf-8, and CSF-1, genes critical for DC differen-
tiation. Furthermore, we showed that DN1-derived DCs 
promote the differentiation of naive CD4+ T cells into Treg 
cells in vitro and de novo CD25+FoxP3+ natural Treg cell 
(nTreg cell) enrichment in vivo by a mechanism that required 
MHCII expression on the DC surface. Finally, we identified 
the physiological relevance of this treatment in a spontaneous 
autoimmune model (T1D). Thus, we reveal a novel function 
for Dll4–Notch as an Flt3-independent pathway essential for 
regulating tDC homeostasis and suppressing autoimmunity.
RESULTS
Nicastrin inactivation induces tDC and Treg cell enrichment
Recent findings suggest that N1 is potentially implicated in 
alternative DC lineage development in thymus (Feyerabend 
et al., 2009; Cheng et al., 2010). In addition, the existence of 
a homeostatic feedback loop between DCs and Treg cells 
(Darrasse-Jèze et al., 2009; Swee et al., 2009) has been re-
vealed. To confirm and extend previous studies, we addressed 
the question of whether Notch receptor signaling inhibition 
could affect both tDC and Treg cell homeostasis. We condi-
tionally deleted Nicastrin (Ncstn/), a -secretase signaling 
component located downstream of the Notch receptor 
(N1–4) signaling cascade (Klinakis et al., 2011). We found that 
Nicastrin deficiency induced an accumulation of pro-T cells 
at DN1 stage (CD4CD8c-kit+CD44+CD25) without 
affecting the final stage of T cell differentiation (CD4+, CD8+ 
T cells; not depicted). Within thymus, we observed an 
increased frequency (two- to fivefold) of plasmacytoid DCs 
(pDCs; CD11c+B220+/PDCA-1+; P < 0.01), conventional 
DCs (cDCs; CD11c+B220; P < 0.01), and immature DCs 
(imDCs; CD11c+MHCIIlo; P < 0.05) in Ncstn/ mice 
(Fig. 1 A, left). The expansion of these cells was not reflected 
in absolute numbers because of a severe reduction in thymic 
cellularity upon Notch signaling blockade (Fig. 1, A [right] 
and B), as previously observed in several studies using genetic 
N1 inactivation models (Hozumi et al., 2008; Koch et al., 
2008; Feyerabend et al., 2009). Thus, Nicastrin deletion 
mimics the effect of N1 deficiency on balancing T versus DC 
development (Feyerabend et al., 2009). Similarly, Ncstn/ 
mice showed a fivefold increase in the frequency of Treg cells 
(P < 0.001; Fig. 1 C), although this expansion was not 
reflected in absolute numbers (Fig. 1 D, left) because of the 
overall decrease of thymic cellularity. Surprisingly, we observed 
an enrichment of Treg cells compared with effector T cells 
(Teff cells; CD4+CD25FoxP3) in thymus, as demonstrated 
by a sixfold increase in the ratio of Treg cell versus Teff cell 
numbers (P < 0.001; Fig. 1 D, right). Thus, a majority of 
is the essential and nonredundant N1 receptor ligand 
(Koch et al., 2008), and its specific inactivation on thymic 
epithelial cells (TECs) leads to a block in T cell development 
accompanied by ectopic appearance of an alternative B cell 
lineage within the thymus (Koch et al., 2008). Recently, 
using pharmacological Dll4 blockade, we showed that ongo-
ing Dll4–Notch signaling is required for T cell homeostasis in 
the thymi of both young and aged mice (Billiard et al., 2011). 
Thus, sustained Dll4–N1 signaling is necessary for maintain-
ing the T cell lineage fate and inhibiting the potential of early 
T cell progenitors to generate alternative lineages (Hozumi 
et al., 2008).
The role of Notch signaling in the development of al-
ternative lineages in thymus has been recently revisited, as 
controversial results about its specific impact on DC differen-
tiation have been reported (Radtke et al., 2000; Feyerabend 
et al., 2009; Cheng et al., 2010; Di Santo, 2010). Although 
initial experiments using mice reconstituted with BM 
precursors deficient for N1 displayed normal DC frequen-
cies in thymus and periphery (Radtke et al., 2000), a study 
showed that embryonic stem cells lacking N1 had a severely 
reduced capacity to generate DCs (Cheng et al., 2010). More-
over, a recent study demonstrated that deletion of N1 under 
the control of Cpa3, a gene encoding mast cell carboxypep-
tidase A, converted pro-T cells to mature DCs (mDCs) in 
thymus (Feyerabend et al., 2009). It has been established 
that thymic DCs (tDCs) originate from hematopoietic stem 
cells, yet their immediate precursors have been more diffi-
cult to identify (Wu et al., 1996; Merad and Manz, 2009). 
Current evidence suggests that a majority of DCs are gener-
ated from early intrathymic precursors (Merad and Manz, 
2009; Zhou et al., 2009) versus a minority that derives ex-
trathymically and continually migrates into the thymus (Wu 
and Shortman, 2005; Li et al., 2009). Thus, although there 
is increasing evidence implicating N1 in the development 
of intra-tDCs, the involvement of the Notch pathway and 
specifically the role of Dll4 in this process, as well as the 
molecular signals promoting Notch-mediated tDC expan-
sion, remain unknown.
tDCs are thought to participate in central tolerance by 
negative selection of autoreactive T cells (Brocker et al., 
1997) and/or induction of regulatory T cells (Treg cells; 
Watanabe et al., 2005). Treg cells (CD4+CD25+FoxP3+  
T cells) are specialized lymphocytes that play a major role in 
maintaining immune tolerance (Sakaguchi et al., 2008) and 
suppressing the development of organ-specific autoimmune 
diseases such as type 1 diabetes (T1D; Salomon et al., 2000; 
Tarbell et al., 2004; Darrasse-Jèze et al., 2009). Recently, a 
regulatory feedback loop between DCs and Treg cells in the 
periphery has been described (Darrasse-Jèze et al., 2009; 
Swee et al., 2009). Moreover, it has been demonstrated that 
Fms-like tyrosine kinase 3 ligand (Flt3-L) is sufficient and 
essential for the development of blood and peripheral lym-
phoid organ DCs (Waskow et al., 2008) and that loss of Treg 
cells increases DC division via an Flt3–dependent mechanism 
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and 16-, seven-, and fivefold increases 
of B cell (P < 0.001), DC (P < 0.001), 
and Treg cell frequencies (P < 0.001), 
respectively, which were not reflected 
in absolute numbers, suggesting an enrichment but not an 
expansion of these populations in thymus (Fig. 2, A and B). 
These data support a role for Dll4 in B cell (Billiard et al., 
2011) and potentially in DC and Treg cell homeostasis. No 
significant changes were detected in splenic DC populations 
(not depicted). Overall, these results show that a sustained 
signal requiring both Dll4 and -secretase–Notch is needed 
to suppress the alternative DC enrichment in thymus.
We have recently shown that anti-Dll4 Ab induces accu-
mulation of pro-T cells at DN1 stage and ectopic appearance 
of B cells within the thymus (Billiard et al., 2011). As genetic 
inactivation of Nicastrin and Dll4, respectively, induces an 
increase in the frequencies but a reduction in the absolute 
numbers of DCs and Treg cells in thymus, we decided to 
investigate the effect of a blocking anti-Dll4 Ab treatment 
on DC homeostasis in adult mice before the severe reduction 
in thymic cellularity takes place. Indeed, pharmacological Dll4 
blockade allowed us to study the kinetics of alternative DC 
development, which is impossible by conventional genetic 
inactivation models in which a severe reduction in thymic 
cellularity has already occurred at the time of sacrifice (Hozumi 
et al., 2008; Feyerabend et al., 2009). 7 d after anti-Dll4 Ab 
treatment, we found a significant increase in both frequency 
and absolute numbers of B cells (P < 0.001; Billiard et al., 2011), 
CD4+ T cells within the thymus were FoxP3+CD25+, dem-
onstrating that an enrichment of thymic Treg cells had oc-
curred upon Notch signaling blockade. Treg cell enrichment 
was also observed in Ncstn/→WT BM chimeras (P < 
0.01), suggesting a cell-autonomous effect (Fig. 1 E). Dll4 
blockade using anti-Dll4 Ab (Billiard et al., 2011) had no 
significant additive effect in these chimeras (Fig. 1 E). We 
conclude that Notch signaling is potentially important for 
maintaining both tDC and Treg cell homeostatic balance under 
steady-state conditions.
Dll4–Notch signaling inhibition induces  
reversible tDC and Treg cell expansion  
and accumulation in the thymic cortical region
To investigate the effect of Dll4–Notch signaling blockade 
on tDC homeostasis, we conditionally deleted Dll4 using 
ROSA26-CreERt2+/Dll4-COIN adult mice treated with 
tamoxifen (Economides, A., personal communication). We 
found that Dll4 deficiency led to a developmental delay be-
tween DN1 and double-positive (DP; CD4+CD8+) T cell 
stage in thymus without significantly affecting CD4+ or CD8+ 
T cell homeostasis (Billiard et al., 2011; unpublished data). 
Similar to Nicastrin deletion, genetic inactivation of Dll4 in-
duced a strong reduction of thymic cellularity (not depicted) 
Figure 1. Nicastrin inactivation induces 
tDC and Treg cell enrichment. (A) Percent-
ages (left) and absolute numbers (right) of 
pDCs (CD11c+B220+/PDCA-1+), cDCs 
(CD11c+B220), and imDCs (CD11c+MHCIIlo) 
in Ncstnf/fMx1-Cre+ mice (Ncstn/) versus 
WT littermates after 3.5 wk of polyI:C treat-
ment. Baseline levels in untreated WT mice 
are shown. (B) Thymus cellularity in Ncstn/ 
mice versus WT littermate controls. (C) Per-
centages of Treg cells (FoxP3+CD25+) among 
CD3+CD4+ cells. (D) Absolute numbers of  
Treg cells (left) and proportion of Treg cell ver-
sus Teff cell numbers in thymus (right). A–D 
show pooled data from three independent 
experiments with two to three mice per group.  
(E) Treg cell enrichment in thymus of WT→ or 
Ncstn/→WT BM chimeras upon anti-Dll4 
or control Ab treatment for 2 wk. Percentages 
of Treg cells (FoxP3+CD25+) among CD3+CD4+ 
cells (left), absolute numbers (middle), and 
proportion of Treg cell versus Teff cell numbers 
(right) are shown. Statistical significance was 
calculated for each group compared with the 
control (Ctr) group. Data are from one experi-
ment with three to five mice per group. Error 
bars represent the mean ± SD. Horizontal bars 
indicate the mean. *, P < 0.05; **, P < 0.01;  
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Figure 2. Dll4–Notch signaling inhibition induces a reversible tDC and Treg cell enrichment and accumulation in the cortical region.  
(A and B) pDC (CD11c+B220+/PDCA-1+), cDC (CD11c+B220), and B cell (B220+CD11c; A) and Treg cell (FoxP3+CD25+ among CD3+CD4+; B) enrichment in 
thymus of vehicle (corn oil)- versus tamoxifen (TAM-induced Dll4 inactivation)-treated ROSA26-CreERt2+/Dll4-COIN mice. Data are from one experiment 
with five mice per group. (C) C57BL/6 mice were treated every 3 d for 3, 7, 14, or 21 d with anti-Dll4 or control Ab (p.i., postinjection). Dot plots show  
B cell, pDC, and cDC percentages among total thymocytes (day 7). Bar graphs show kinetics of enrichment of global mDCs (CD11c+MHCII+), which include 
pDCs and cDCs, in percentages (top) and absolute numbers (bottom). (D) Kinetics of imDC (CD11c+MHCIIlo) enrichment in percentages (top) and absolute 
numbers (bottom) after treatment with anti-Dll4 or control Ab. Dot plots show day 7. (E) Dot plots (day 14, left) and graphs reflect Treg cell frequencies 
(right) in thymus upon anti-Dll4 versus control Ab treatment in C57BL/6 mice. C–E show pooled data from three independent experiments with four to 
five mice per group (day 3, one experiment). (F) Treg cell absolute numbers (left) in thymus upon anti-Dll4 versus control Ab treatment in C57BL/6 mice. 
Bar graphs (right) reflect the proportion of Treg cell numbers versus Teff cell numbers in thymus. Graphs show pooled data from two to four independent 
experiments with five mice per group (day 3, one experiment). (G) Apoptosis of cells in thymus (AnnexinV+), determined within viable cells (nonnecrotic),  
3 or 7 d after treatment with anti-Dll4 Ab. mDC, Treg cell, and Teff cell percentages were determined within total thymocytes. (H) Bar graphs (top) show 
relative messenger RNA expression of Notch receptors (N1–4) in sorted DC subsets (imDCs, pDCs, and cDCs) and pro-T cells (DP and DN). Histograms (bot-
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signaling blockade induces ectopic appearance and accumu-
lation of both DCs and Treg cells in the cortical area. To 
examine whether the homeostatic effect of anti-Dll4 Ab treat-
ment on DCs and Treg cells was reversible, WT C57BL/6 mice 
were treated with control or anti-Dll4 Ab for 7 d. As pre-
viously described (Fig. 2, C, D, and F), we found that Dll4 
inhibition induced a significant increase in imDC and mDC 
(tDC) and Treg cell numbers (P < 0.01). After cessation of treat-
ment (4 wk, “recovery”), both tDC and Treg cell numbers 
returned to baseline levels (Fig. 2 J). This result is consistent 
with the previous finding showing that anti-Dll4 Ab washes 
out 2–3 wk after treatment arrest (Billiard et al., 2011). Thus, 
sustained Dll4–Notch signaling blockade is required for 
maintaining alternative tDC and Treg cell expansion.
MHCII expression by DCs is required for in vivo  
Treg cell enrichment upon anti-Dll4 Ab treatment
It has been shown that tDCs contribute to Treg cell induction 
(Watanabe et al., 2005). To examine whether DN1-derived 
DCs induce in vitro Treg cell differentiation, CD25FoxP3 
CD4+ single-positive (SP) or CD25FoxP3 DP T cells 
purified from the thymus of untreated mice (purity >99%; 
not depicted) were incubated with tDCs sorted from anti-
Dll4– or control-treated animals in the presence of IL-2, a 
cytokine required for Treg cell differentiation and survival 
(Almeida et al., 2002). It is known that FoxP3 induction can 
occur at either the DP or CD4 SP stage in thymus or during 
the transition between these stages (Fontenot et al., 2005a). 
Interestingly, we observed a significantly higher FoxP3 ac-
quisition in both DP and CD4 SP T cells (3.8- and 2.2-fold, 
respectively) upon culture with tDCs purified from mice 
previously treated with anti-Dll4 Ab– versus isotype control–
treated animals (Fig. 3 A). This result suggests a potential 
tolerogenic effect of DN1-derived tDC populations. Further-
more, although Treg cell proliferation in response to cultured 
DCs appears to be independent of MHCII (Swee et al., 
2009), a separate study shows that homeostatic Treg cell divi-
sion requires self-antigen presentation by MHCII because it 
is impaired in MHCII KO mice (Shimoda et al., 2006). In 
addition, a recent work demonstrates that Flt3-dependent 
DC increase in the periphery leads to increased homeostatic 
Treg cell division and accumulation by a mechanism requiring 
MHCII expression on DCs (Darrasse-Jèze et al., 2009). To 
determine whether Dll4-mediated thymic Treg cell enrich-
ment (Fig. 2 F) was DC dependent, CD11chi DCs were 
ablated by administration of diphtheria toxin (DT) in CD11c-
DTR→WT BM chimeras (Jung et al., 2002) throughout 
3 wk of anti-Dll4 treatment. DC deficiency abrogated the 
effect of anti-Dll4 Ab treatment on Treg cell frequency in-
crease (Fig. 3 B), thus demonstrating the essential role of DCs 
mDCs (comprising cDCs and pDCs; not depicted; P < 0.01), 
and imDCs (P < 0.01) within the thymus (Fig. 2, C and D). 
Upon several injections with the anti-Dll4 Ab given over 14 
or 21 d, the expansion of B cells and DCs was not reflected 
in absolute cell numbers (Fig. 2, C and D; and not depicted) 
as the result of a severe drop in thymic cellularity (Billiard 
et al., 2011), as expected and as observed upon genetic inac-
tivation of Dll4 (Fig. 1 and Fig. 2, A and B). Furthermore, we 
found that Dll4 blockade induced an increase in both fre-
quency and absolute numbers of Treg cells (CD3+CD4+CD8 
CD25+FoxP3+) and Treg cell precursors (CD3+CD8+CD4+ 
CD25+FoxP3+) in thymus at day 7 (Fig. 2, E and F [left]; and 
not depicted). As previously reported (Billiard et al., 2011), 
2 wk after treatment, this was not reflected in absolute cell 
numbers because of the severe drop in thymic cellularity. 
However an enrichment of Treg cells among CD4+ T cells 
was observed within the thymus as demonstrated by a seven- 
to ninefold increase in the ratio of Treg cell/Teff cell numbers 
(P < 0.001; Fig. 2 F, right). Furthermore, we found that anti-
Dll4 Ab treatment did not promote apoptosis of thymocytes, 
mDCs, Treg cells, or Teff cells compared with control Ab 
treatment and that DCs and Treg cells were not more resistant 
to apoptosis than Teff cells or total thymocytes, as no differ-
ence in the apoptosis rates were detected 3 and 7 d after Ab 
treatment (Fig. 2 G; Billiard et al., 2011). In the periphery, 
no mDC enrichment was observed upon anti-Dll4 treatment 
(not depicted). We further examined the expression levels of 
Dll4 and Notch receptors on sorted pDCs, cDCs, imDCs, 
and early T cell progenitors. We found that Dll4 is not con-
stitutively expressed on DCs and/or splenocytes (not de-
picted). Expression of N1–4 receptors remained undetectable 
on DCs, whereas N1 expression was high on double-negative 
(DN) pro-T cells (Fig. 2 H). We conclude that pharmaco-
logical Dll4 blockade induces DC and Treg cell expansion in 
thymus 1 wk after treatment and an enrichment of these cell 
populations at later time points.
tDCs and CD25+FoxP3+ nTreg cells are predominantly 
accumulated in the medullary region of the thymus and 
sparsely detectable in the cortex (Fontenot et al., 2005b; Lei 
et al., 2011). To determine whether anti-Dll4 treatment 
affects the anatomical distribution of DCs and Treg cells, 
FoxP3gfp mice (Fontenot et al., 2005b) were treated with anti-
Dll4 versus control Ab for 7 d. Thymic sections were stained 
for TECs and DCs. Measurement of tDC density in vari-
ous thymic regions indicated that the number of tDCs and 
FoxP3gfp+ (Treg) cells per unit area in the deep cortical region 
was significantly (P < 0.001) increased in anti-Dll4–treated 
compared with control mice (Fig. 2 I). No detectable change 
in the absolute numbers of DCs and Treg cells was observed 
in the medullary region (Fig. 2 I). We conclude that Dll4–Notch 
from WT FoxP3gfp C57BL/6 mice treated with anti-Dll4 versus control Ab for 7 d and stained for GFP (green), CD11c (red), and mTEC (blue). Bars, 50 µm. 
CD11c+ and GFP+ cell counts are shown (bottom). (J) imDC (top), mDC (middle), and Treg cell (bottom) absolute numbers in thymus upon anti-Dll4 or con-
trol Ab treatment. Mice treated for 7 d were then allowed to recover without treatment for 4 wk (recovery). G–J show pooled data from two independent 
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Early DC precursors (pre-DCs), imDCs, and mDC sub-
sets (pDCs and cDCs) arise from the common precursors 
called macrophage DC progenitors (MDPs) and the common 
DC progenitors (CDPs) located in the BM (Waskow et al., 
2008; Liu et al., 2009; Geissmann et al., 2010). To examine 
whether anti-Dll4 Ab treatment has a direct effect on BM-
derived DC progenitors, LinSca-1c-kit+CSF-1–R+ (MDP) 
and LinSca-1c-kitloCSF-1–R+Flt3+ (CDP) populations 
(Liu et al., 2009) were assessed after 3, 7, 14, and 21 d of 
treatment. We found that MDPs and CDPs were undetect-
able in spleen and thymus but present in the BM. Surpris-
ingly, no expansion of either MDPs or CDPs was observed 
in BM upon anti-Dll4 Ab treatment (Fig. 4 A). Furthermore, 
no effect was observed in imDC and mDC frequencies and 
absolute numbers (Fig. 4 B). Therefore, tDC enrichment is 
not caused by a homeostatic effect of anti-Dll4 Ab treatment 
on early or late BM-derived DC progenitors.
tDCs could either originate independently of the T cell 
pathway or branch off no later than the DN1 pro-T cell 
stage (Wu et al., 1996; Radtke et al., 2000). Deleting N1 in 
pro-T cells converts them to DCs, suggesting that intra-
thymically generated T cells and DCs could share a common 
early precursor (Feyerabend et al., 2009). In addition, N1 
signaling has a role in the development of alternative lineages 
such as NK and B cells in thymus (Di Santo, 2010). To deter-
mine the origin of the early tDC expansion upon Dll4 
blockade, we first examined the kinetics of appearance of 
imDCs within the DN1 population. We observed a threefold 
increase in the frequency and the absolute number of imDCs 
originating from the DN1 population as early as day 3 after 
anti-Dll4 Ab treatment, whereas an increase in mDC abso-
lute number was detected only 7 d later in the same popula-
tion (Fig. 4 C). We found that DCs did not show a higher 
proliferative potential (Fig. 4 C, top right) after anti-Dll4 Ab 
treatment, suggesting that this Ab treatment does not en-
hance proliferation of an existing tDC pool. No expansion 
in NK cells, granulocytes, macrophages, or B cells was de-
tected after the same treatment within the DN1 population 
(Fig. 4 D). To further examine whether imDC expansion 
could originate from uncommitted early T cell precursors, 
an equal number of DN1 CD45.1+Lin sorted cells that did 
not express CD11c and/or MHCII (not depicted) was trans-
ferred by intrathymic injection into CD45.2+ host mice 
treated with anti-Dll4 or control Ab. As expected, anti-Dll4 
treatment induced an endogenous DC expansion compared 
with control (Fig. 4 E, bottom; and Fig. 2, C and D). More 
importantly, we found that upon Dll4 blockade, CD45.1+ 
DN1 cells acquired an imDC phenotype and were signifi-
cantly expanded in thymus (Fig. 4 E, top; P < 0.01). Interest-
ingly, hardly any CD45.1+, CD4+, or CD8+ SP cells were 
detected in the control Ab–treated mice (not depicted), most 
likely because the vast majority of DN1-transferred cells 
were eliminated during T cell negative selection by deletion 
and neglect after their differentiation into TCR+ cells (Pénit 
et al., 1995; van Meerwijk et al., 1997). Indeed, based on the 
kinetics of thymocyte development and the fact that a 
in Dll4-mediated Treg cell enrichment. To investigate the 
role of MHCII expression by DCs in Treg cell homeostasis 
in vivo, CD11c-Cre/I-Abflox mice that lacked MHCII ex-
pression on CD11chi cells (not depicted) and had fewer Treg 
cells than littermate controls (Darrasse-Jèze et al., 2009) were 
treated with control or anti-Dll4 Ab. We found that anti-
Dll4–mediated Treg cell enrichment was impaired in CD11c-
Cre/I-Abflox mice compared with control mice (Fig. 3 C). 
We conclude that Dll4–Notch signaling inhibition promotes 
thymic Treg cell generation by a mechanism that requires 
MHCII expression on DCs.
Anti-Dll4 Ab treatment converts early  
T cell progenitors to imDCs
To determine whether tDC expansion at day 3 and/or 7 was 
caused by an extra-tDC migration via the blood stream (Wu 
and Shortman, 2005; Merad and Manz, 2009), DC homeo-
stasis was evaluated in blood upon anti-Dll4 Ab treatment. 
We found that DC numbers were not affected in peripheral 
blood (not depicted), suggesting that anti-Dll4–mediated DC 
expansion could originate either intrathymically or via ex-
pansion of DC progenitors from the BM.
Figure 3. Anti-Dll4 Ab–mediated enrichment of Treg cells is  
dependent on DC-expressing MHCII. (A) Thymic CD25FoxP3 DP (left) 
or CD4 SP (right) T cells from WT mice were cultured with CD11c+ tDCs 
from anti-Dll4– or control Ab–treated mice and IL-2. The expression of 
FoxP3/CD25 was assessed after 3 d of culture. (B) CD11c-DTR→WT BM 
chimeras were injected with anti-Dll4 or control Ab twice a week for 14 d, 
along with DT to sustain DC deficiency. Percentages of Treg cells were de-
termined in thymus. (C) CD11c-Cre/I-Abflox+/ or CD11c-Cre/I-Abflox/ 
mice were treated with anti-Dll4 or control Ab twice a week for 14 d, and 
percentages of Treg cells were determined in thymus. Each panel shows 
pooled data from two independent experiments with four to five mice per 
group for each panel. Error bars represent the mean ± SD. *, P < 0.05;  
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Pharmacological Dll4 inhibition induces alternative tDC 
development via an Flt3-independent mechanism
The mechanism by which Notch signaling (N1 or Dll4) block-
ade induces alternative tDC development (Fig. 4; Feyerabend 
et al., 2009) remains unknown. Thus, we further investigated 
the molecular signals promoting alternative tDC enrichment. 
It has been shown that Flt3-L is able to drive differentiation 
of mouse BM progenitors into all DC subtypes (Brasel et al., 
2000; Merad and Manz, 2009) and is sufficient and essential 
for the development of blood and peripheral lymphoid organ 
DCs (Waskow et al., 2008). Mice lacking Flt3-L show an 
eightfold reduction in the number of cDCs in the spleen 
remarkably large fraction of thymocytes do not reach matu-
rity as a result of overriding negative selection in the pres-
ence of physiological ligands expressed on hematopoietic 
cells, >90% of developing thymocytes die of neglect and 
5–8% die as a result of deletion or another unknown mecha-
nism (Huesmann et al., 1991; Surh and Sprent, 1994). Thus, 
we can speculate that because anti-Dll4 Ab treatment con-
verts CD45.1+ DN1 cells into alternative cell types such as 
DCs, it rescues them from early T cell development check-
points. We conclude that anti-Dll4 Ab treatment promotes 
the intrathymic development of imDCs originating from a 
common T/DC DN1 progenitor.
Figure 4. Anti-Dll4 Ab treatment converts pro-T cells to imDCs, independently of BM progenitors. (A) MDP (LinSca-1c-kit+CSF-1–R+) and 
CDP (LinSca-1c-kitloCSF-1–R+Ftl3+) percentages in BM, thymus, and spleen of C57BL/6 mice 3 d after treatment with anti-Dll4 or control Ab. NF, not 
found. (B) CD11c+MHCIIlo DC (imDC) and CD11c+MHCII+ mDC percentages (top) and absolute numbers (bottom) in BM upon anti-Dll4 versus control Ab 
treatment. A and B show pooled data from two independent experiments with five mice per group. (C) Dot plots (day 3) show percentages of imDCs and 
mDCs in DN1 pro-T cells (CD4CD8c-kit+CD44+CD25) upon anti-Dll4 versus control Ab treatment. Percentages of proliferating (Ki67+DAPI+) imDCs 
found within DN1 are shown in anti-Dll4 Ab– or control Ab–treated mice (top right). Bar graphs show percentages (left) and absolute numbers (right) of 
imDCs (top) and mDCs (bottom) within DN1 cells. (D) Fold increase in percentages of imDCs, mDCs, NK cells (NK1.1+CD3), Gr1+CD11b+ cells, macro-
phages (MAC-1+F4/80+), and B cells (B220+CD11c) in DN1 pro-T cells in thymus upon treatment (day 3) with anti-Dll4 Ab. (E) Dot plots show imDCs 
among CD45.1+ DN1-transferred cells (top) or among CD45.2+ endogenous DN1 cells (bottom) in CD45.2+ C57BL/6 recipient mice treated every 3 d with 
anti-Dll4 or control Ab and sacrificed 9 d after first injection. Quadrants were set with isotype controls for CD11c and MHCII Abs. The bar graph shows 
absolute numbers of imDCs in CD45.1+ cells. C–E show data from three independent experiments with five mice per group. Error bars represent the  








niversity user on 19 August 2020
1018 a-Dll4 promotes thymic DC and Treg development | Billiard et al.
(McKenna et al., 2000; unpublished data), and additional 
studies show that the rate of cDC division in lymphoid or-
gans is regulated in part by Flt3 receptor signaling (Steinman, 
2007; Waskow et al., 2008). To determine whether the effect 
of anti-Dll4 Ab was mediated by Flt3-L, bioactive Flt3-L was 
measured in the serum of treated mice. No detectable modi-
fication of Flt3-L serum levels was observed (not depicted). 
To validate this result, mice lacking either Flt3-L (Flt3-L/) 
or its receptor (Flt3-R/) were treated with anti-Dll4 Ab 
for 7 or 21 d. Surprisingly, we found that a significant increase 
in both frequency and DC number indeed occurred in the 
thymus of both Flt3-R/ (P < 0.001; Fig. 5 A) and Flt3-L/ 
(P < 0.05; Fig. 5 B) mice at day 7. We further show that 
DC-dependent Treg cell expansion observed 7 d after anti-
Dll4 treatment took place in an Ftl3-independent manner as 
demonstrated by an increase of Treg cell frequency and abso-
lute cell numbers in both Flt3-R/ (P < 0.05) and Flt3-L/ 
(P < 0.05) mice (Fig. 5 C, left). As expected, 21 d after anti-
Dll4 treatment, this Treg cell expansion was not reflected in 
absolute numbers (Fig. 5 C, right) because of a drop in thy-
mic cellularity. Rather, the treatment induced an accumula-
tion of Treg cells among the CD4+ effector cell population 
in thymus, as demonstrated by an increase in the ratio of 
Treg cells/Teff cells (not depicted). We conclude that Dll4–
Notch signaling blockade induces an Flt3-independent tDC 
and subsequent Treg cell expansion. Therefore, we propose 
that Dll4–Notch functions as a novel alternative pathway 
regulating tDC homeostasis.
The ability of early T cell progenitors to rederive toward a 
non-T cell phenotype has been observed (Di Santo, 2010). 
Here, gene array analysis was performed in purified thymo-
cytes and DN1 cells (defined and sorted as CD4CD8 
c-kit+CD44+CD25; not depicted) to determine the effect of 
anti-Dll4 Ab treatment in genes implicated in T versus DC and 
B cell lineage specification. As previously described (Matsuzaki 
et al., 1993; Billiard et al., 2011), c-kit was used as a DN1 cell 
surface marker, as CD44 is also expressed in B cells and other 
myeloid cells. We recently showed that the Notch signaling 
pathway (Hes1, Ptcra, and Deltex-1) is inhibited upon anti-
Dll4 treatment (Billiard et al., 2011). Here we found that 
CD11c gene present in fully differentiated DCs and DC pre-
cursors was intact (not depicted). In contrast, we observed a 
down-regulation of genes essential for T cell commitment, 
Figure 5. Pharmacological Dll4 inhibition induces alternative tDC 
development via an Flt3-independent mechanism. (A and B) 
CD11c+MHCII+ mDC percentages (left) and absolute numbers (right) in 
thymus of Flt3-R/ (A) and Flt3-L/ (B) mice 7 d after anti-Dll4 versus 
control Ab treatment. (C) Treg cell percentages (top) and absolute numbers 
(bottom) in thymus of Flt3-R/ and Flt3-L/ mice 7 (left) or 21 d (right) 
after anti-Dll4 versus control Ab treatment. (D and E) Gene array analysis 
showing T, B, and DC gene signatures in total thymocytes and FACS-
sorted LinCD11c DN (CD4CD8) and LinCD11c DN1 (CD4CD8 
c-kit+CD44+CD25) from anti-Dll4– versus control Ab–treated C57BL/6 
mice. Data reflect the ratio of expression (in log2) between anti-Dll4/con-
trol (Ctr) treatment. (F) CSF-1 serum levels in C57BL/6 mice untreated or 
treated with anti-Dll4 or control Ab. (G) Proposed mechanism involving 
Dll4–Notch signaling in T cell versus DC/B fate decisions and expansion of 
Treg cells. CLP, common lymphoid progenitor. A–F show pooled data from 
two independent experiments with five mice per group for each panel. 
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Anti-Dll4 Ab treatment prevents T1D  
via a Treg cell–mediated mechanism
We further examined whether anti-Dll4 Ab treatment could 
have an effect on peripheral Treg cell homeostasis. It is known 
that imDCs have low MHCII and co-stimulatory molecule 
expression (Marguti et al., 2009), and we observed expansion 
of these cells in thymus upon anti-Dll4 Ab treatment under 
steady-state conditions. Our data (Fig. 3 A) suggest that 
DN1-derived imDCs could have a potential tolerogenic ef-
fect such as inducing Treg cell expansion (Darrasse-Jèze et al., 
2009; Swee et al., 2009). A nonsignificant increase in splenic 
Treg cells was observed after 21 d of Dll4–Notch signaling 
blockade under steady-state conditions (Fig. 6 A), whereas in 
the presence of an inflammatory stimulus (CFA/OVA or 
polyinosinic:polycytidylic acid [polyI:C] in Ncstn/ mice), 
a significant increase in both Treg cell frequency and absolute 
numbers was observed (Fig. 6, A and B; and not depicted). 
Importantly, no expansion of peripheral Treg cells was ob-
served in adult thymectomized mice compared with WT 
controls treated with anti-Dll4 Ab in the presence of CFA/
OVA, suggesting that Dll4–Notch signaling blockade gener-
ated nTreg cells in thymus (Fig. 6, A and B). To confirm that 
anti-Dll4 Ab treatment induced natural versus inducible Treg 
whereas genes (Lyl1 and PU.1) that can each block T cell 
development (Di Santo, 2010) if sustained beyond this point 
were up-regulated (Fig. 5, D and E). Most interestingly, genes 
controlling DC (PU.1 [Carotta et al., 2010] and Spi-B) and 
B cell development (Merad and Manz, 2009) were also up-
regulated (Fig. 5 E). In addition, expression of RelB and Id2, as 
well as IRF2 and IRF4, key transcription factors involved in 
DC subset development (Merad and Manz, 2009), were in-
creased (Fig. 5 E). To validate this result, PU.1, Spi-B, and 
IRF4 expression were also measured by quantitative PCR (not 
depicted). Finally, gene expression and serum levels of CSF-1 
(M-CSF), a key cytokine involved in DC development 
(Fancke et al., 2008), were found to be up-regulated (P < 0.05; 
Fig. 5 F). Thus, Dll4–Notch signaling blockade down-regulated 
transcription factors specific for T cell lineage commitment, 
while up-regulating others crucial for DC development. Over-
all, we conclude that Dll4–Notch signaling is essential for sus-
taining proper T cell development and homeostasis, whereas 
its inhibition triggers an Flt3-independent pathway regulat-
ing tDC development and subsequent Treg cell differentia-
tion (Fig. 5 G). Thus, we sought to investigate the physiological 
relevance of this pathway and its potential consequences in 
immune suppression and autoimmunity.
Figure 6. Anti-Dll4 Ab induces the expansion of thymus-derived nTreg cells in the periphery upon immune stimulation. (A) Treg cell expansion 
upon anti-Dll4 versus control Ab treatment in spleens of nonimmunized or CFA/OVA-immunized normal or thymectomized C57BL/6 mice. Fold increase in 
percentages (top) or absolute numbers (Abs nb; bottom) are shown. (B) Expansion of splenic Treg cells in percentages (top) or absolute numbers (bottom) 
after treatment with anti-Dll4 or control Ab in WT or thymectomized C57BL/6 mice upon CFA/OVA immunization. (C) FoxP3/CD25 expression in CD4+ cells 
of CD45.2+ recipient or of CD45.1+CD4+FoxP3CD25 injected (donor) cells in C57BL/6 mice upon treatment with control or anti-Dll4 Ab for 21 d.  
(D) Percentages of proliferating (Ki67+DAPI+) Treg cells in thymus of anti-Dll4– or control (Ctr) Ab–treated C57BL/6 mice at day 7 after start of treatment.  
(E) Expression of Helios and GITR (left) and pStat5 (day 14; middle) on thymic Treg cells upon anti-Dll4 Ab treatment in C57BL/6 mice. Teff cell are shown as 
a negative control for pStat5 expression. The gate of analysis was set with isotype control. (right) Detection of total Stat5 (tStat5) and pStat5 protein in 
total thymocytes and purified thymic Treg cells upon 7 d of anti-Dll4 Ab treatment. mm, molecular mass. A–E show pooled data from two independent 
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population but rather induces a de novo generation of thymic 
nTreg cells. We conclude that Dll4–Notch signaling regulates 
the homeostasis of nTreg cells via a DC-mediated MHCII-
dependent mechanism (Fig. 3 C), without promoting expan-
sion of inducible Treg cells.
We further investigated the physiological relevance of anti-
Dll4 Ab treatment in blocking a spontaneous autoimmune dis-
ease (T1D) using nonobese diabetic (NOD) mice and examining 
whether Treg cells mediated its effect. Compared with control 
Ab–treated animals that showed high diabetes incidence (>80%), 
we found that anti-Dll4 Ab treatment fully prevented disease 
development (Fig. 7 A). Disease protection was correlated with 
high Treg cell frequency (Fig. 7 A, inset), high ratio of Treg cell/
Teff cell numbers in pancreas-draining LNs (PLNs; not depicted), 
and lack of CD8+ cell infiltration in the pancreatic islets of anti-
Dll4–treated animals (Fig. 7 B). In addition, as previously shown 
in WT C57BL/6 mice, a significant enrichment of Treg cells 
(Fig. 2 E), DCs (Fig. 2 C), B cells, and DN1 pro-T cells (Billiard 
et al., 2011) was observed in thymus of anti-Dll4–treated NOD 
mice (not depicted). To determine whether anti-Dll4 Ab treat-
ment could prevent T1D by DC-mediated Treg cell expansion, 
mice were treated with anti-Dll4 Ab for 10 wk. After cessation 
of treatment, a cohort of mice was injected with anti-CD25 
(PC61) Treg cell–depleting Ab, whereas another cohort received 
PC61 isotype control. We found that anti-Dll4–mediated pro-
tection was significantly decreased in anti-CD25 Ab–treated 
animals. In contrast, mice treated with PC61 isotype control re-
mained normoglycemic, suggesting that diabetes relapse was not 
caused by cessation of anti-Dll4 Ab treatment but by Treg cell 
cells, polyclonal CD45.1+CD4+FoxP3CD25 T cells (purity 
>99%; not depicted) were adoptively transferred into CD45.2+ 
recipient animals treated with control or anti-Dll4 Ab and 
immunized with CFA/OVA. We found that polyclonal 
CD4+ T cells remained negative for FoxP3 upon anti-Dll4 
treatment, whereas expanded endogenous nTreg cells were 
detected in thymus (P < 0.001) and spleen (P < 0.05; Fig. 6 C). 
We also assessed Treg cell division by staining for the prolif-
eration marker Ki67. A similar frequency of proliferating 
FoxP3+ Treg cells was observed in thymus upon anti-Dll4 
compared with isotype control treatment (Fig. 6 D). Finally, 
we further characterized the phenotype of anti-Dll4–mediated 
Treg cells by showing expression of GITR, known to be asso-
ciated with Treg cell function (McHugh et al., 2002), and 
high expression of Helios and phosphorylated Stat5 (pStat5), 
both markers of nTreg cell differentiation (Fig. 6 E; Thornton 
et al., 2010; Goldstein et al., 2011). Neither the percentage of 
pStat5+ Treg cells nor the expression of the aforementioned 
markers was altered by anti-Dll4 treatment (Fig. 6 E). A more 
detailed quantitation of Stat5 and pStat5 levels showed a small 
but reproducible increase of pStat5 levels in thymocytes of 
mice treated with anti-Dll4 Ab. Remarkably, although treat-
ment did not affect the levels of the phosphorylated form in 
Treg cells, it resulted in a pronounced decrease of the non-
phosphorylated form (tStat5, total Stat5). Therefore, the ratio 
between the phosphorylated/activatory and nonphosphory-
lated species of Stat5 was greatly increased upon Dll4 block-
ade (Fig. 6 E, right). Overall, these results suggest that Dll4 
blockade does not induce expansion of a preexisting Treg cell 
Figure 7. Anti-Dll4 Ab prevents T1D via a Treg cell–mediated mechanism and inhibition of pancreatic islet infiltration. (A) Diabetes incidence 
of NOD mice treated with anti-Dll4 or control Ab starting at 8 wk of age. One injection of CD25-depleting Ab (PC61) or isotype Ab was administrated to 
anti-Dll4–treated mice at 20 wk of age. (inset) Percentages of Treg cells in nondraining LNs (green) or PLNs (red). The number of treated mice is indicated. 
(B) Immunostaining of pancreas sections from NOD mice treated with anti-Dll4 versus control (Ctr) Ab, stained for islets and CD8. (C) H&E staining of 
pancreatic sections from control (left)-, anti-Dll4 Ab (middle)–, or anti-Dll4/PC61 Ab–treated (right) NOD mice. Bars: (B) 50 µm; (C) 100 µm. (D) Islets were 
counted on whole pancreas section from the mice from C. Percentage of infiltration was determined (right). A–D show representative data from two  
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1999), few studies report disease treatment (Belghith et al., 
2003; Tang et al., 2004). Recently, it has been shown that 
multiple injections of a low dose of IL-2 at diabetes onset can 
induce disease remission in 60% of mice (Grinberg-Bleyer 
et al., 2010). To determine whether anti-Dll4 Ab could treat 
T1D, NOD mice were injected with a single dose of anti-
Dll4 Ab at the time of disease onset, with or without anti-
CD25 Ab. We observed decreased blood glucose to normal 
levels (<200 mg/dl) in 100% of anti-Dll4–treated mice (Fig. 8 A 
and not depicted) for a sustained period (4 wk). When we 
simultaneously injected anti-Dll4 and anti-CD25 Abs, disease 
relapse took place 1 wk earlier versus injection with anti-Dll4 
Ab alone, suggesting that anti-Dll4 Ab treatment has a thera-
peutic effect via a Treg cell–mediated mechanism. This hy-
pothesis is strengthened by the fact that during T1D remission 
depletion (Fig. 7 A). Finally, anti-Dll4 Ab treatment signifi-
cantly prevented pancreatic islet infiltration (P < 0.001) and 
subsequent destruction (P < 0.05; Fig. 7, C and D). We further 
investigated the effect of Treg cell depletion (PC61 treatment) on 
pancreatic islet infiltration. Mice previously treated with anti-
Dll4 Ab (disease free) that received a PC61 injection upon 
cessation of anti-Dll4 Ab treatment (T1D relapse) showed a se-
vere increase in the percentage of islet infiltration (P < 0.001; 
Fig. 7 D). We conclude that anti-Dll4 Ab treatment fully pre-
vents T1D development via a Treg cell–mediated mechanism 
and inhibits pancreatic islet infiltration.
Anti-Dll4 Ab treatment reverses established T1D
Although several methods of preventing T1D in NOD mice 
have been described over the years (Atkinson and Leiter, 
Figure 8. Anti-Dll4 Ab reverses established T1D. (A) Blood glucose levels in NOD mice treated at diabetes onset (250 < glucose level < 350 mg/dl) 
with control or anti-Dll4 Ab, alone or with 1 mg PC61 Ab the same day. The number of treated mice is indicated. Representative data are shown from 
three independent experiments. (B) Percentages (left) and absolute numbers (middle) of Treg cells in nondraining LNs (green) or PLNs (red) of NOD mice 
untreated (time point 1, diabetic) or treated with anti-Dll4 Ab (time points 2, remission; and 3, relapse). Absolute numbers of Treg cells in spleen of NOD 
mice treated with control (open bar) or anti-Dll4 Ab (closed bar; time point 2) are shown (right). Data were pooled from three independent experiments 
with five mice per group. (C) Expression of FoxP3, Helios, GITR, CTLA-4, and pStat5 in organs of control (diabetic)- versus anti-Dll4 Ab–treated (diabetes 
remission) NOD mice. Graphs show representative data from two independent experiments with four mice per group. (D) MFI (mean fluorescence inten-
sity; as calculated by MFI(Ab)  MFI(isotype)) of CD69, CD62L, and FoxP3 on Treg cells from PLNs of NOD mice. Data were collected from mice at specific 
stages of disease/treatment across three independent experiments. (E) Suppressive activity of purified Treg cells from spleen of diabetic versus anti-Dll4 
Ab–treated mice, represented in cpm (left) or percent inhibition (right). Data were pooled from two independent experiments with three mice per group. 
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numbers because of the decreased cellularity in thymus the 
day of sacrifice. Anti-Dll4 Ab gave us the ability to examine 
the kinetics of tDC expansion before the reduction of thymic 
cellularity occurs, a task impossible to perform by conven-
tional genetic inactivation studies (Hozumi et al., 2008; Koch 
et al., 2008; Feyerabend et al., 2009). Importantly, we ob-
served a significant increase in imDC absolute number within 
DN1 pro-T cells as early as 3 d after anti-Dll4 treatment, fol-
lowed by an expansion of mDC and Treg cell absolute num-
bers 7 d later when thymic cellularity was not yet severely 
reduced. The same treatment did not promote expansion 
of NK cells, granulocytes, or macrophages within the DN1 
population. These findings suggest that although the majority 
of the enriched populations detected within the DN1 cells 
and the cortical thymic area are DCs and Treg cells, the effect 
of Notch signaling blockade in DC-dependent Treg cell ex-
pansion is reflected in absolute numbers only 1 wk after treat-
ment, as at later time points (days 14 and 21) this increase is 
not sufficient to compensate for the robust decrease in the 
overall thymic cellularity. Furthermore, anti-Dll4 treatment 
did not promote apoptosis of thymocytes, DCs, Treg cells, or 
Teff cells, and no difference in the apoptosis rate between 
DCs and Treg cells versus Teff cells and thymocytes was de-
tected upon treatment. Notably, we have previously shown 
that our anti-Dll4 Ab specifically blocks Dll4 function and 
does not promote death of Dll4-expressing cells (TECs) or 
T helper cells; therefore, it does not alter the thymic environ-
ment and the final stages of T cell development (Billiard 
et al., 2011). Moreover, we demonstrated that anti-Dll4 Ab 
converts early canonical T cell progenitors to DCs, which 
subsequently promote de novo nTreg cell generation rather 
than endogenous Treg cell proliferation or conversion of nTreg 
cells to inducible Treg cells. Overall, we conclude that as DCs 
do not show a higher proliferative potential and have a simi-
lar apoptosis rate to thymocytes and Teff cells, it seems that 
anti-Dll4 Ab treatment does not enhance proliferation of an 
existing tDC pool but rather converts DN1 progenitors to 
DCs. This Dll4-mediated conversion represents a source of 
continuous tDC generation that could account for the in-
crease in absolute tDC number. To further support the func-
tional relevance of the anti-Dll4–mediated Treg cell expansion, 
we demonstrated that in an inflammatory setting (CFA/OVA 
administration and T1D), anti-Dll4 treatment of NOD mice 
at diabetes onset induces a significant increase in Treg cell 
number in the periphery, as opposed to what we observed 
under steady-state conditions. This Treg cell expansion directly 
correlates with T1D remission. Indeed, Treg cell–depleting 
PC61 treatment together with anti-Dll4 administration sig-
nificantly accelerated T1D relapse compared with the treat-
ment with anti-Dll4 Ab alone. Thus, we demonstrated that 
anti-Dll4 treatment initiates an expansion of Treg cells neces-
sary for T1D remission. These findings suggest a role for 
Dll4–Notch signaling in Treg cell homeostasis and provide 
evidence for the functional relevance of Dll4-mediated Treg 
cells in the treatment of T1D. Finally, we found that the 
effect of the anti-Dll4 Ab in tDC and nTreg cell expansion is 
(2 wk after treatment), Treg cell frequency (P < 0.001), abso-
lute number (P < 0.05; Fig. 8 B), and Treg cell/Teff cell num-
ber ratio (P < 0.001; not depicted) were significantly increased 
in the PLNs and spleen (P < 0.05; Fig. 8 B, right) of anti-
Dll4– versus isotype control–treated mice. Confirming pre-
vious results shown in Fig. 6, we found that Dll4-mediated 
Treg cells were nTreg cells based on their sustained expression 
of FoxP3, Helios, GITR, CTLA-4, and pStat5 in thymus, 
spleen, and blood as well as in the PLNs of treated (disease 
free) animals. No differences in expression levels of these mark-
ers were detected compared with endogenous nTreg cells 
found in diabetic animals (Fig. 8 C). However, we found that 
anti-Dll4 treatment induced up-regulation of CD69, an early 
activation marker (Sancho et al., 2005), in PLNs (Fig. 8 D) and 
spleen (not depicted). Upon T1D relapse, CD69 expression 
returned to low levels, whereas CD62L, a homing recep-
tor, was up-regulated, suggesting a potential tissue relocaliza-
tion of these cells (Cyster, 1999). FoxP3 expression was 
sustained upon T1D relapse (Fig. 8 D). Finally, we confirmed 
that anti-Dll4–mediated nTreg cells were functional based on 
their ability to suppress T cell proliferation ex vivo (Fig. 8 E). 
Importantly, we found that after T1D recurrence (4 wk after 
anti-Dll4 treatment and Ab washout), the frequency and 
number of Treg cells and the ratio of Treg cells/Teff cells in 
PLNs returned to baseline levels (Fig. 8 B) as observed in dia-
betic mice, providing evidence for an existing link between 
anti-Dll4 Ab treatment, Treg cell frequency, and disease inci-
dence. Thus, we propose using Dll4 blockade to suppress es-
tablished autoimmune diabetes.
DISCUSSION
In this study, we have described a novel function for Dll4–
Notch signaling as an Flt3-alternative pathway essential for 
regulating tDC homeostasis with potential implications in the 
treatment of autoimmunity. Anti-Dll4 Ab treatment induced 
development of immature tDCs originating from early T cell 
precursors (DN1 stage, CD4CD8c-kit+CD44+CD25) in 
an Flt3-independent manner, implicating transcription factors 
critical for DC differentiation (PU.1, Spi-B, Irf-4, and CSF-1). 
DN1-derived tolerogenic DCs promoted in vitro differentia-
tion of naive CD4+ T cells into Treg cells. Furthermore, Dll4–
Notch signaling inhibition induced CD25+FoxP3+ nTreg cell 
enrichment by a DC-dependent mechanism that required 
MHCII expression on DCs in vivo. Finally, pharmacological 
Dll4 blockade suppressed T1D via a Treg cell–mediated 
mechanism and inhibited pancreatic islet infiltration. Impor-
tantly, a single injection of Dll4 Ab reversed established T1D, 
whereas disease remission and recurrence were correlated 
with increased and decreased Treg cell numbers, respectively, 
in the PLNs.
In agreement with previous studies demonstrating that 
genetic inactivation of N1 or Dll4 severely reduces thymic 
cellularity (Hozumi et al., 2008; Koch et al., 2008; Feyerabend 
et al., 2009; Billiard et al., 2011), we observed that both 
Nicastrin and Dll4 deletion induced a significant increase in 
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Takeichi et al., 2010). N1–4 expression remains undetectable 
on the DC surface (Merad and Manz, 2009), whereas N1 is 
highly expressed on DN thymocytes as expected (Fiorini et al., 
2009). Thus, we hypothesized that anti-Dll4 Ab does not 
have a direct effect on DC precursors or differentiated splenic 
DCs but must preferentially inhibit the interaction between 
TECs expressing Dll4 and DN thymocytes expressing N1 to 
convert these DN1 thymocytes to a DC phenotype.
The underlying mechanism by which Notch signaling 
blockade induces and sustains alternative tDC development 
has not been explored to date. Here, we demonstrate that 
anti-Dll4 Ab treatment is sufficient to promote an immature 
tDC differentiation, surprisingly via an Flt3-independent 
mechanism, as mice lacking either Flt3-L (Flt3-L/) or its 
receptor (Flt3-R/) showed a significant increase in DC 
numbers upon Dll4–Notch signaling blockade. A gene array 
experiment using purified thymic pro-T cells showed that 
suppression of Dll4–Notch signaling up-regulated transcrip-
tion factors (e.g., PU.1, RelB, Id2, Irf2, Irf4, and Irf8) and 
CSF-1 cytokine, which are crucial for DC subset develop-
ment and differentiation. Consistent with our findings, a re-
cent study showed that conditional ablation of PU.1 leads to 
a severe reduction in both cDC and pDC numbers in thymus 
mediated by Flt3-L or other key targets of PU.1 such as 
GM-CSF, GM-CSFR, CD11b, CSF-1, Irf4, and Irf8 (Carotta 
et al., 2010). Furthermore, anti-Dll4 Ab treatment induced 
enrichment of CD25+FoxP3+ nTreg cells via a DC-mediated 
MHCII-dependent mechanism. Although Flt3 is considered to 
be essential for DC development in the BM and in healthy 
mouse brain (Liu and Nussenzweig, 2010; Anandasabapathy 
et al., 2011) and an important component in controlling the 
DC–Treg cell regulatory feedback loop (Darrasse-Jèze et al., 
2009), our results revealed the existence of two signaling 
pathways (Flt3 and Dll4–Notch) that both can promote a re-
versible DC-dependent nTreg cell expansion but function in-
dependently in two anatomically distinct locations, periphery 
and thymus, respectively. Indeed, the Flt3 pathway favors a 
sustained proliferation of nTreg cells in the periphery (Darrasse-
Jèze et al., 2009), whereas Dll4–Notch promotes a de novo 
nTreg cell differentiation in thymus. In addition, our study 
provided in vitro and in vivo evidence for the tolerogenic 
potential of DN1-derived DCs in generating Treg cells. Over-
all, this finding reveals a novel role for Dll4 in regulating tDC 
and the subsequent Treg cell homeostasis.
Using the NOD spontaneous autoimmune T1D mouse 
model, we showed that anti-Dll4 Ab treatment prevented 
diabetes development by inhibiting CD8+ cell pancreatic islet 
infiltration and promoted enrichment of functional nTreg cells 
able to suppress T cell proliferation ex vivo. In addition, 
simultaneous injection of anti-Dll4 and anti-CD25 (PC61) 
Treg cell–depleting Ab caused T1D relapse, suggesting an 
important role for anti-Dll4–mediated Treg cells in disease 
prevention. An additional potential mode of action for anti-Dll4 
Ab in T1D prevention could implicate the inhibition of T cell 
differentiation toward a Th1 phenotype important in T1D 
development (Esensten et al., 2009; Takeichi et al., 2010). 
reversible. Overall, these results demonstrate that a sustained 
Dll4–Notch signaling blockade is required to maintain alter-
native DC development in the thymus, promote early DC 
and Treg cell expansion followed by an enrichment of Treg 
cells in thymus, and induce Treg cell expansion in the periph-
ery upon immune stimulation.
Anti-Dll4 Ab treatment did not induce accumulation of 
tDCs and Treg cells in the medullary area, but rather it favored 
accumulation of these cells in the cortex. In a recent study, Lei 
et al. (2011), using Xcl1-deficient mice, showed a reduction 
of tDC and Treg cell numbers in thymic medulla, suggesting a 
potential role for this protein in the medullary accumulation 
of tDCs and Treg cell generation. Here, gene array data showed 
an up-regulation of XCL1, along with chemokine receptors 
(CCR2, CCR5, CCR7, and CXCR4) known for their role in 
cell migration (Sallusto et al., 1998). Further investigation is 
required to address whether overexpression of XCL1 and 
chemokine receptors could lead to ectopic appearance and 
accumulation of DCs and Treg cells in the thymic cortex.
Current evidence suggests that a majority of DCs are 
generated from early intrathymic T cell precursors (Wu and 
Shortman, 2005; Li et al., 2009; Merad and Manz, 2009; 
Zhou et al., 2009). However, a recent study proposed a DC 
potential of intrathymic precursors found within the DN1 
population that originate from BM DC progenitors and do 
not share a common origin with pro-T cells (Luche et al., 
2011). In contrast, another study demonstrated that genetic 
inactivation of N1 converted early T cell progenitors to DCs 
that contain TCR D1–J1 rearrangements, thus providing 
evidence for the existence of a common T/DC precursor 
(Feyerabend et al., 2009). In agreement with this work, we 
found that alternative tDC differentiation originating from 
early T cell progenitors is mediated by Dll4–Notch signaling 
blockade and that a sustained signal requiring the Dll4–Notch 
signaling pathway is needed to suppress early tDC expansion. 
Indeed, a gene array study on purified DN1 cells showed that 
anti-Dll4 Ab treatment does not modify the expression of 
genes (CD11c) found in DC precursors and in fully differen-
tiated DCs, but it rather down-regulates genes involved in 
T cell differentiation while up-regulating others (PU.1 and 
SpiB) crucial in DC development. Moreover, no major mod-
ification was observed in peripheral DC homeostasis upon 
pharmacological blockade or Dll4 deficiency, suggesting that 
peripheral DCs are not directly affected by this treatment. 
Our findings are in agreement with a previous study showing 
that N1 deficiency has no effect on splenic DC subsets 
(Feyerabend et al., 2009). In contrast, a separate study shows 
that recombinant binding protein (RBP-Jk), a molecule 
implicated in Notch receptor signaling cascade, seems to play 
an intrinsic role in the maintenance and survival of peripheral 
CD8 mDCs. However, its selective requirement in CD8 
DCs is correlated with the specific and RBP-Jk–dependent 
expression of Notch target Deltex1 by this population (Caton 
et al., 2007). In addition, it is known that Dll4 is not consti-
tutively expressed on DCs and/or splenocytes, but rather its 
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In summary, our results support the existence of a novel 
Flt3-alternative pathway involved in tolerogenic tDC devel-
opment and subsequent MHCII-dependent nTreg cell enrich-
ment. Under physiological conditions, this pathway is suppressed 
in the presence of ongoing Dll4–Notch signaling. These fea-
tures of Dll4–Notch signaling extend our knowledge by 
linking Notch and DC biology and revealing a potential 
pathway for controlling Treg cell homeostasis that could be 
used as therapeutic treatment in autoimmunity.
MATERIALS AND METHODS
Mice. 6-wk-old C57BL/6 (CD45.2+ and CD45.1+) and female NOD mice 
(The Jackson Laboratory) were housed in our animal facility. COIN (condition-
als by inversion) Dll4 transgenic mice were obtained by crossing ROSA26-
CreERt+ with Dll4-COIN mice, resulting in F1 mice that expressed the 
Dll4-COIN gene in all tissues. Inversion of the reading sequence and thus 
inactivation of Dll4 was induced by the injection of tamoxifen (2 mg/animal/d) 
emulsified in corn oil for 5 d. Mice were sacrificed 2.5 wk later. Control 
mice were injected with corn oil only. Ncstnf/fMx1-Cre+/+ mice (Klinakis 
et al., 2011; Ncstn/) were injected starting at 3 wk of age with polyI:C for 
2 wk to induce inactivation of Notch receptor signal transduction. The mice 
were sacrificed 3.5 wk later. Ncstn/→WT BM chimeras were obtained 
by BM transplantation from Ncstn/ mice (or from WT C57BL/6 for 
controls) into lethally irradiated C57BL/6 recipient mice. 8 wk later, mice 
were injected twice a week for 3 wk with control or anti-Dll4 Ab. CD11c-
Cre/I-Abflox mice (Darrasse-Jèze et al., 2009) and FoxP3gfp mice (Fontenot 
et al., 2005b) were used at 6 wk of age. CD11c-DTR→WT chimeras were 
obtained by BM transplantation from CD11c-DTR mice into lethally irra-
diated C57BL/6 recipient mice. 8 wk later, mice were injected twice a week 
for up to 13 d with DT along with control or anti-Dll4 Ab. Flt3-R/ and 
Flt3-L/ mice (Darrasse-Jèze et al., 2009) were injected at 12 wk of age 
with control or anti-Dll4 Ab. Animal housing and procedures were reviewed 
and approved by Regeneron Pharmaceuticals, Inc.’s internal animal care and 
use committee.
Anti-Dll4 Abs. By immunizing VelocImmune mice, which express the full 
repertoire of human Ab variable domains in the endogenous locus of the 
mouse immunoglobulin gene, we discovered an array of Dll4 Abs that bind 
to various domains of Dll4 and efficiently block the interaction of Dll4 with 
Notch receptors. Further characterization was performed on 40 of these Abs, 
which represent a significant diversity of repertoire and bind Dll4 with an 
affinity of <1 nM, in cell-based and biochemical assays. A subset of these Abs 
was further tested using in vivo assays, and one (anti-Dll4 Ab) that recognizes 
both human and mouse Dll4 was selected for use in these experiments, 
which allowed investigation of thymic changes in WT mice (i.e., non-Dll4 
humanized). These Abs were both previously tested (Billiard et al., 2011). 
Human Fc (IgG1; control Ab) was used as a control.
Ab treatments. C57BL/6, WT→ or Ncstn/→WT BM chimeras, 
Flt3-R/, Flt3-L/, CD11c-Cre/I-Abflox mice, and CD11c-DTR→WT 
chimeras were injected subcutaneously with 25 mg/kg anti-Dll4 or control 
Ab twice a week for 1, 2, or 3 wk depending on the experiment. For pro-
phylactic treatment, NOD mice were injected at 8 wk of age, once a week 
for 10 wk. For therapeutic treatment, NOD mice were injected once at dia-
betes onset, with or without 1 mg anti-CD25 PC61 Ab. For Treg cell deple-
tion in prophylactic treatment, NOD mice were left 2 wk without anti-Dll4 
Ab treatment and then were injected intraperitoneally with 1 mg anti-CD25 
PC61 Ab or isotype control (rat IgG1).
Cell preparations. Thymi and spleens were collected and gently dissoci-
ated between frosted slides. BM was collected by flushing femurs. All cells 
were strained after dissociation or flushing and washed in PBS 1× 3% fetal 
bovine serum for staining.
Strikingly, a single injection of anti-Dll4 Ab reversed estab-
lished T1D via a Treg cell–dependent mechanism. The corre-
lation between disease remission and increased Treg cell 
numbers in both PLNs and spleen, Ab washout after treat-
ment cessation (Billiard et al., 2011), and the return of Treg 
cell numbers to baseline upon disease recurrence suggests an 
important role for the Dll4–Notch signaling pathway in the 
treatment of T1D. Few studies have reported the reversal of 
an early diabetes onset with sufficient efficiency: only succes-
sive daily injections of low doses of IL-2 (Grinberg-Bleyer 
et al., 2010) or anti-CD3 Ab (Belghith et al., 2003) or high 
quantities of in vitro–expanded islet-specific Treg cells (Tang 
et al., 2004) had this effect. Our treatment is highly efficient 
in that a single injection reverses hyperglycemia in 100% 
of mice within a few days, although a certain therapeutic 
window of 250–350 mg/dl of blood glucose level must 
apply. Although anti-CD25 Ab treatment shortens the diabe-
tes remission time, thus strongly suggesting a Treg cell–medi-
ated mechanism, the fast remission we observed is unlikely to 
be solely the result of Treg cell proliferation, as it would take 
several days for these cells to expand enough. Because Dll4 
and Notch signaling have been shown to play multiple roles 
in diverse biological pathways, such as in cell development 
and differentiation (i.e., of endothelial cells [Hellström et al., 
2007] and intestinal stem cells [Pellegrinet et al., 2011]) and 
in angiogenesis (Gale et al., 2004; Noguera-Troise et al., 
2006), it is possible to speculate that multiple modes of action 
could be occurring here. In fact, it has recently been shown 
that pharmacological blockade of Notch signaling with 
-secretase inhibitors raises insulin sensitivity in both lean 
and obese insulin-resistant mice (Pajvani et al., 2011). It is 
conceivable that the fast reduction of blood glucose levels 
observed in our system may be insulin mediated. Although 
further investigation is needed to better understand this com-
plex mechanism, our data suggest that Dll4 blockade pro-
motes a DC-dependent Treg cell expansion necessary for 
disease remission. Finally, we showed that nTreg cells gener-
ated upon anti-Dll4 Ab treatment were not qualitatively dif-
ferent from the endogenous nTreg cells found in the diabetic 
mice, but rather were outnumbered. Our data are in agree-
ment with a previous study showing that Treg cells from 
diabetic and diabetes-free NOD mice (20–25 wk old at this 
stage) similarly suppress the proliferation of Teff cells from 
prediabetic NOD mice, as in our system (Gregori et al., 
2003). The percentage of inhibition was low (30%), as previ-
ously described in NOD mice of this age (You et al., 2005). 
In addition, it has been suggested that lower frequencies of 
Treg cells in T1D patients compared with healthy controls 
could participate in the development of the disease (Kukreja 
et al., 2002) and that polyclonal Treg cell enrichment is suffi-
cient and essential to suppress autoimmunity (Darrasse-Jèze 
et al., 2009). Therefore, the overall outcome of the anti-Dll4 
Ab treatment in an autoimmune disease setting could be 
caused by a DC-dependent Treg cell amplification cascade origi-
nating in thymus and leading to peripheral Treg cell expansion 
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taken from that chip. The transcripts that were differentially abundant be-
tween anti-Dll4 Ab and control Ab treatments were identified. Comparisons 
between two groups for continuous variables were made with a Student’s 
t tests. Results were considered statistically significant if P < 0.05. Microarray 
data were deposited in GEO DataSets under accession number GSE24296.
ELISA. For the detection of Flt3-L and CSF-1, sera from mice were col-
lected, and manufacturer’s instructions were followed (R&D Systems).
Cell injections and immunization. For intrathymic injections, DN1 
pro-T cells from thymus of CD45.1+ C57BL/6 mice were magnetically enriched 
using anti-CD4/CD8 beads (Miltenyi Biotech) and then sorted on a MoFlo 
(Beckman Coulter) based on their LinCD3CD4CD8c-kit+CD25CD11c 
expression. Recipient CD45.2+ mice were anesthetized with ketamine and 
xylazine, the thoracic cage was carefully opened to expose the thymus, and 105 
DN1 cells were injected using a 10-µl Hamilton syringe. Recipient mice were 
injected with 25 mg/kg anti-Dll4 or control Ab 24 h before the surgery and 
right after recovery. The injections were pursued every 3 d until day 9 after 
surgery, the time of sacrifice. For Teff cell transfers, OVA-specific (OTII) cells 
from C57BL/6 mice were magnetically enriched using a Regulatory T Cell 
Isolation kit (Miltenyi Biotech). The CD4+CD25 fraction was kept and as-
sessed for FoxP3 expression before injection. Mice were immunized subcuta-
neously with a 100-µg emulsion of CFA and OVA.
In vitro culture of tDCs and T cells. tDCs were enriched from anti-
Dll4– or control-treated mice using anti-CD11c magnetic beads (Miltenyi 
Biotech) with two consecutive positive selections. Purity was >90%. Thy-
mic CD4+CD25FoxP3 T cells were enriched from WT C57BL/6 mice 
using a Regulatory T Cell Isolation kit with two consecutive negative selec-
tions for CD25. T cells were cultured at 106/ml with DCs (ratio T/DC, 5:1) 
and 0.5 µg/ml hIL-2 (R&D Systems) for 3 d.
Western blot of pStat5/Stat5. Enriched thymic CD4+CD25FoxP3  
T cells (with a Regulatory T Cell Isolation kit) were lysed by boiling in SDS 
sample buffer (Invitrogen). Proteins were analyzed by PAGE and transferred 
to polyvinylidene fluoride membranes. After blocking, the indicated pro-
teins were probed using Abs specific for Stat5 or pStat5 (Cell Signaling 
Technology) or actin (Abcam). Membranes were then incubated with an 
anti–rabbit or anti–mouse Ab conjugated to horseradish peroxidase. Proteins 
were visualized by addition of SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific) and exposure to x-ray film.
Proliferation assay. Enriched splenic Treg cells (CD4+CD25+) and Teff cells 
(CD4+CD25) from NOD mice were obtained with a Regulatory T Cell 
Isolation kit. The purity of CD4+CD25+ cells exceeded 98% (cells were 
>98% FoxP3+) after three consecutive positive selections, and the contami-
nation of Teff cells by CD25+FoxP3+ cells was <3%. 2 × 104 Teff cells and 
irradiated syngeneic T cell–depleted splenocytes from 4-wk-old prediabetic 
NOD mouse were cultured with or without 2 × 104 Treg cells for 3 d in 
U-bottomed 96-well plates, with 3 µg/ml anti-CD3 mAb (145-2C11; BD) 
and pulsed with [Methyl-3H]thymidine (1 µCi/well) for the last 6–8 h of 
culture. Cells were collected on a Filtermate Harvester, and thymidine dis-
integration (cpm) was counted on a TopCount (PerkinElmer). The percent-
ages of inhibition were calculated as follows: percent inhibition = 100  
(cpm with Treg cells/cpm Teff cells alone) × 100.
Statistical analysis. Statistical significances were calculated using the two-
tailed unpaired Student’s t test with 95% confidence intervals (*, P < 0.05; 
**, P < 0.01; ***, P < 0.001).
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Abs for flow cytometric analysis. The following Abs were used: for 
DCs, Sirp-a (P84), B220 (RA3-6B2), PDCA-1 (eBio927), CD8 (53-6.7), 
CD11b/MAC-1 (M1/70), MHCII (M5/114.15.2), CD11c (N418), and 
CD135 (A2F10); for T cells, CD45.1 (A20), CD4 (GK1.5 or L3T4), CD3 
(145-2C11), CD25 (PC61 or 7D4), FoxP3 (FJK16s), N1 (mN1A), Ki67 
(20Raj1), Helios (22F6), GITR (DTA-1), CTLA-4 (WKH203), pStat5 
(47), CD69 (H1.2F3), and CD62L (MEL-14); for progenitors, Sca-1 (D7), 
c-kit (2B8), CD115 (CSF-1–R; AFS98), and CD135 (Flt3-R; A2F10); and 
Lin gate was NK1.1 (PK136), Ter119 (TER-119), Gr1 (RB6-8C5), CD19 
(eBio1D3; all from eBioscience except Sirp-a, CD45.1, and pStat5 from BD 
and Helios from BioLegend). DAPI was used at 10 µg/ml for proliferation 
assay (Invitrogen). Necrotic cells were excluded from analysis using Live/
Dead Fixable Dead Cell Stain kit (Invitrogen). FoxP3 staining buffer set 
(eBioscience) was used to stain Treg cells. Cells were acquired on an LSRII 
(BD), and data were analyzed using FlowJo software (Tree Star).
Diabetes and glucose monitoring. NOD mice were checked for glucose 
levels once a week (or twice at the time of the onset) using a OneTouch 
mini glucometer (LifeScan). The mice were considered diabetic after two 
consecutive readings >250 mg/dl. Diabetes occurred between 15 and 20 wk 
of age in our animal facility.
Histology. Pancreases were harvested in 10% buffered formalin (Thermo 
Fisher Scientific). After 24 h, the organs were transferred in ethanol 70%. 
Sections and hematoxylin and eosin (H&E) staining were performed by 
Histoserv, Inc.
Immunofluorescence analysis. Tissues were fixed in 4% PFA and per-
fused with 30% sucrose before freezing in optimal cutting temperature com-
pound (Sakura). Frozen tissue was sliced into 10-µm-thick sections, postfixed 
with acetone, and stained with the following Abs: for thymus, mTEC- 
specific Ab MTS-10 (BD), Alexa Fluor 647–conjugated anti-IgM (Invitro-
gen), DC-specific CD11c-biotin (clone N418; BD), and Alexa Fluor 
555–conjugated streptavidin (Invitrogen); FoxP3 promoter-driven GFP was 
detected by Alexa Fluor 488–conjugated anti-GFP (Invitrogen); for pancreas, 
islets were stained with guinea pig anti-insulin (Dako) and DyLight- 
649–anti–guinea pig (Jackson), human antiglucagon (Regeneron Pharmaceu-
ticals, Inc.) and DyLight-649–anti–human (The Jackson Laboratory), 
CD8-biotin (BD), and Alexa Fluor 488–streptavidin (Invitrogen). Images 
were acquired on an inverted laser-scanning confocal microscope (SP2 [Leica] 
or LSM 510 [Carl Zeiss]) using a 40× or 25× objective. Images were analyzed 
using ImageJ software (National Institutes of Health).
Quantitative PCR. Total RNA was isolated using the RNeasy Plus Mini 
kit (QIAGEN), and cDNA was synthesized using the SuperScript First-
Strand kit (Invitrogen). Quantitative PCR was performed using SYBR green 
iMaster and a LightCycler 480 (Roche). The following primer sequences 
were used (melting temperature = 60°C used for all primers): mN1 forward, 
5-TGCCTGTGCACACCATTCTGC-3; and reverse, 5-CAATCAGA-
GATGTTGGAATGC-3; mNotch2 forward, 5-ATGCACCATGACAT-
CGTTCG-3; and reverse, 5-GATAGAGTCACTGAGCTCTCG-3; 
mNotch3 forward, 5-TTGGTCTGCTCAATCCTGTAGC-3; and re-
verse, 5-TGGCATTGGTAGCAGTTGCTG-3; and mNotch4 forward, 
5-AAGCGACACGTACGAGTCTGG-3; and reverse, 5-ATAGTTGC-
CAGCTACTTGTGG-3.
Whole mouse genome oligonucleotide microarray. RNA from each 
sample was amplified by TargetAmp 2-Round Aminoallyl-aRNA Amplifi-
cation kit (Epicentre). Amplified cRNAs were labeled with Cyanine 3 and 
hybridized to custom arrays comprising of 43,538 60-mer oligonucleotides 
covering the whole mouse transcriptome (Agilent Technologies). Hybrid-
ized microarrays were scanned on a Microarray scanner (Agilent Technolo-
gies). Raw data were extracted from scanned array images using Feature 
Extraction 9.5.1.1 (Agilent Technologies). Global normalization was per-
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